Phase II Study of Fractionated 90Y Ibritumomab tiuxetan (ZevalinTM) as initial therapy of Follicular Lymphoma.

Trial Profile

Phase II Study of Fractionated 90Y Ibritumomab tiuxetan (ZevalinTM) as initial therapy of Follicular Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2016

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Rituximab
  • Indications Follicular lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms FIZZ
  • Most Recent Events

    • 02 Dec 2013 Status changed from active, no longer recruiting to completed according to results published in Journal of Clinical Oncology.
    • 15 Dec 2011 Bayer as trial company, lead trial centre and additional location (France) added as reported by ClinicalTrials.gov.
    • 15 Dec 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top